Clinical trial
Melphalan With BBBD in Treating Patients With Brain Malignancies
NCT00253721 · OHSU Knight Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00253721 |
|---|---|
| Title | Melphalan With BBBD in Treating Patients With Brain Malignancies |
| Official title | Intra-Arterial Melphalan (L-Phenylalanine Mustard) Administered in Conjunction With Osmotic Blood-Brain Barrier Disruption in Patients With Brain Malignancies: A Phase I Study |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer |
| Intervention type | Drug |
| Interventions | Melphalan |
| Enrollment | 21 |
| Start date | May 1, 1998 |
| Primary completion | Dec 1, 2015 |
| Completion | Dec 1, 2016 |
| First posted | Nov 15, 2005 |
| Last update posted | Apr 21, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: